Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group Inc. is poised for significant growth, driven by sustained high-single-digit sales growth and an expected expansion of EBITDA margins from approximately 16% today to the mid-20s in the coming years, highlighting the company's financial resilience. The firm’s solid, unlevered balance sheet provides a strong foundation for future growth initiatives, underpinned by the increasing global adoption of advanced diabetes technologies, which has accelerated over the past 15 years. Furthermore, the International segment's consistent double-digit sales growth, supported by new product launches such as MiniMed Go and the Instinct CGM sensor, positions the company favorably for continued revenue and market share expansion.

Bears say

Minimed Group Inc faces significant challenges that contribute to a negative outlook, including anticipated declines in EPS due to the launch of new products and unresolved regulatory risks related to its pipeline of devices, which could result in delays and increased costs. The company has experienced competitive disadvantages owing to past quality system issues and exhibits low penetration rates in key markets; approximately 26% for Type 1 diabetes and only 6% for intensive Type 2 diabetes patients, indicating underperformance relative to its estimated patient population. Additionally, the company's historical struggles with meeting product development timelines add to the concern, as these delays may position Minimed Group behind faster-moving competitors in the medical technology space.

MMED has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 9 analysts, MMED has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.